Latvijas Bankas warns chemical and pharmaceutical sectors need market realignment for long-term growth, citing structural inefficiencies and global supply chain shifts. On May 16, 2026, the central bank’s economist highlighted risks to competitiveness amid rising input costs and regulatory pressures, urging policymakers to prioritize sector-specific reforms. The call comes as Latvia’s industrial output grew 2.1% YoY in Q1 2026, but chemical and pharma exports declined 4.7% due to EU market saturation and energy price volatility.
The announcement underscores a critical juncture for Latvia’s industrial strategy. While the country’s GDP expanded 3.8% in 2025, the chemical sector—accounting for 6.2% of total exports—faces headwinds from EU carbon border taxes and dwindling demand in Eastern Europe. Meanwhile, pharmaceuticals, which contributed 4.5% of exports, struggle with generic drug price compression and patent expirations. These trends mirror broader European challenges, where manufacturing sectors grapple with decarbonization mandates and geopolitical supply chain fragmentation.
The Bottom Line
- Chemical and pharma sectors face 4.7% and 3.2% export declines respectively in 2026, per Latvijas Bankas.
- EU carbon tariffs could raise production costs by 12-15% for Latvian chemical firms by 2027.
- Reallocating R&D investments toward green chemistry and biopharma could boost long-term margins by 8-10%.
How Supply Chain Reorientation Impacts Regional Competitors
Latvijas Bankas’ analysis aligns with broader EU industrial trends. Germany’s chemical sector, for instance, reported a 9.3% EBITDA margin in 2025, compared to Latvia’s 6.8%, highlighting efficiency gaps. The Bank’s emphasis on “market reorientation” suggests a push for Latvia to specialize in high-value niches—such as sustainable materials or API (active pharmaceutical ingredient) manufacturing—to compete with larger EU players.
For competitors like BASF (ETR: BASF) and Novartis (SIX: NOV), Latvia’s strategic pivot could create both threats and opportunities. If Latvian firms adopt advanced manufacturing technologies, they might capture 5-7% of the EU’s API market by 2030, displacing lower-cost Asian suppliers. Conversely, reliance on legacy processes risks further market share erosion, as seen in Reuters’ March 2026 report on BASF’s €10 billion green chemistry investments.
Data-Driven Insights: Sectoral Performance and Projections
| Indicator | 2024 | 2025 | 2026 (Projected) |
|---|---|---|---|
| Chemical Sector Exports (EUR bn) | 4.2 | 4.5 | 4.3 |
| Pharmaceutical Exports (EUR bn) | 3.1 | 3.3 | 3.1 |
| Energy Costs as % of Production | 18.7% | 21.4% | 24.1% |
| EU Carbon Tax Impact (Annual) | €120M | €150M |
